Verification of candidate microRNA markers for parathyroid carcinoma
Parathyroid carcinoma (PCa) is a rare endocrine malignancy with poor prognosis and is often difficult to accurately diagnose both before and after surgery. Dysregulated microRNA (miRNA) levels have been identified in PCa using a limited number of samples. The aim of the present study was to verify a group of miRNA markers in a new series of samples to explore their potential significance in PCa diagnosis.
A total of 58 tissue samples, including 17 PCa lesions and 41 sporadic parathyroid adenomas (PAds), were obtained from 56 primary hyperparathyroidism (pHPT) patients. Candidate miRNAs (miR-139-5p, miR-155-5p, miR-222-3p, miR-26b-5p, miR-296-5p, miR-30b-5p, miR-372-3p, miR-503-5p, miR-517c-3p, miR-7-5p, and miR-126-5p) were quantified by TaqMan real-time quantitative PCR assays.
Up-regulated miR-222 (p = 0.041) levels and down-regulated miR-139 (p = 0.003), miR-30b (p < 0.001), miR-517c (p = 0.038), and miR-126* (p = 0.002) levels were found in PCa relative to PAd. Binary logistic regression analysis showed that miR-139 and miR-30b were the best diagnostic markers. The combination of miR-139 and miR-30b yielded an area under the receiver operating characteristic curve of 0.888. Additionally, serum calcium (r s = −0.518, p < 0.001), intact parathyroid hormone (iPTH) (r s = −0.495, p < 0.001), and alkaline phosphatase (ALP) (r s = −0.523, p < 0.001) levels were negatively correlated with miR-30b levels.
miR-139, miR-222, miR-30b, miR-517c, and miR-126* were differentially expressed between PCa and PAd. The combined analysis of miR-139 and miR-30b may be used as a potential diagnostic strategy for distinguishing PCa from PAd.
KeywordsParathyroid carcinoma MiRNA Markers RT-qPCR
This work was supported by the Peking Union Medical College Innovative Team Development Program and the Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine (CAMS-I2M) (2017-I2M-1-001).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.G. Di Leva, M. Garofalo, C.M. Croce, MicroRNAs in cancer. Annu. Rev. Pathol. 9, 287–314 (2014). https://doi.org/10.1146/annurev-pathol-012513-104715 CrossRefPubMedGoogle Scholar
- 7.V. Shilo, I.Z. Ben-Dov, M. Nechama, J. Silver, T. Naveh-Many, Parathyroid-specific deletion of dicer-dependent microRNAs abrogates the response of the parathyroid to acute and chronic hypocalcemia and uremia. FASEB J. 29, 3964–3976 (2015). https://doi.org/10.1096/fj.15-274191 CrossRefPubMedGoogle Scholar
- 9.S. Corbetta, V. Vaira, V. Guarnieri, A. Scillitani, C. Eller-Vainicher, S. Ferrero, L. Vicentini, I. Chiodini, M. Bisceglia, P. Beck-Peccoz, S. Bosari, A. Spada, Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr. Relat. Cancer 17, 135–146 (2010). https://doi.org/10.1677/ERC-09-0134 CrossRefPubMedGoogle Scholar
- 11.V. Vaira, F. Elli, I. Forno, V. Guarnieri, C. Verdelli, S. Ferrero, A. Scillitani, L. Vicentini, F. Cetani, G. Mantovani, A. Spada, S. Bosari, S. Corbetta, The microRNA cluster C19MC is deregulated in parathyroid tumours. J. Mol. Endocrinol. 49, 115–124 (2012). https://doi.org/10.1530/JME-11-0189 CrossRefPubMedGoogle Scholar
- 13.M.I. Rather, M.N. Nagashri, S.S. Swamy, K.S. Gopinath, A. Kumar, Oncogenic microRNA-155 down-regulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: implications for cancer therapeutics. J. Biol. Chem. 288, 608–618 (2013). https://doi.org/10.1074/jbc.M112.425736 CrossRefPubMedGoogle Scholar
- 15.R.V. Lloyd, R.Y. Osamura, G. Klöppel, J. Rosai, WHO/IARC Classification of Tumours (4th edn., Volume 10) WHO Classification of Tumours of Endocrine Organs. IARC, Lyon (2017)Google Scholar
- 20.O. Wang, C. Wang, M. Nie, Q. Cui, H. Guan, Y. Jiang, M. Li, W. Xia, X. Meng, X. Xing, Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas. PLoS ONE 7, e45567 (2012). https://doi.org/10.1371/journal.pone.0045567 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.J.D. Carpten, C.M. Robbins, A. Villablanca, L. Forsberg, S. Presciuttini, J. Bailey-Wilson, W.F. Simonds, E.M. Gillanders, A.M. Kennedy, J.D. Chen, S.K. Agarwal, R. Sood, M.P. Jones, T.Y. Moses, C. Haven, D. Petillo, P.D. Leotlela, B. Harding, D. Cameron, A.A. Pannett, A. Höög, H. Heath, L.A. James-Newton, B. Robinson, R.J. Zarbo, B.M. Cavaco, W. Wassif, N.D. Perrier, I.B. Rosen, U. Kristoffersson, P.D. Turnpenny, L.O. Farnebo, G.M. Besser, C.E. Jackson, H. Morreau, J.M. Trent, R.V. Thakker, S.J. Marx, B.T. Teh, C. Larsson, HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat. Genet. 32, 676–680 (2002). https://doi.org/10.1038/ng1048 CrossRefPubMedGoogle Scholar
- 23.C. Pandya, A.V. Uzilov, J. Bellizzi, C.Y. Lau, A.S. Moe, M. Strahl, W. Hamou, L.C. Newman, M.Y. Fink, Y. Antipin, W. Yu, M. Stevenson, B.M. Cavaco, B.T. Teh, R.V. Thakker, H. Morreau, E.E. Schadt, R. Sebra, S.D. Li, A. Arnold, R. Chen, Genomic profiling reveals mutational landscape in parathyroid carcinomas. JCI Insight 2, e92061 (2017). https://doi.org/10.1172/jci.insight.92061 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.F. Cetani, C. Banti, E. Pardi, S. Borsari, P. Viacava, P. Miccoli, L. Torregrossa, F. Basolo, M.R. Pelizzo, M. Rugge, G. Pennelli, G. Gasparri, M. Papotti, M. Volante, E. Vignali, F. Saponaro, C. Marcocci, CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer. Endocr. Connect. 2, 186–195 (2013). https://doi.org/10.1530/EC-13-0046 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.M. Bacci, E. Giannoni, A. Fearns, R. Ribas, Q. Gao, M.L. Taddei, G. Pintus, M. Dowsett, C.M. Isacke, L.A. Martin, P. Chiarugi, A. Morandi, miR-155 drives metabolic reprogramming of ER+ breast cancer cells following long-term estrogen deprivation and predicts clinical response to aromatase inhibitors. Cancer Res. 76, 1615–1626 (2016). https://doi.org/10.1158/0008-5472.CAN-15-2038 CrossRefPubMedGoogle Scholar
- 30.A.R. Glover, J.T. Zhao, A.J. Gill, J. Weiss, N. Mugridge, E. Kim, A.L. Feeney, J.C. Ip, G. Reid, S. Clarke, P.S. Soon, B.G. Robinson, H. Brahmbhatt, J.A. MacDiarmid, S.B. Sidhu, MicroRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. Oncotarget 6, 36675–36688 (2015). https://doi.org/10.18632/oncotarget.5383 CrossRefPubMedPubMedCentralGoogle Scholar
- 33.A.M. Silva-Figueroa, N.D. Perrier, Epigenetic processes in sporadic parathyroid neoplasms. Mol. Cell. Endocrinol. (2017). https://doi.org/10.1016/j.mce.2017.04.007
- 34.W. Liu, H. Li, Y. Wang, X. Zhao, Y. Guo, J. Jin, R. Chi, MiR-30b-5p functions as a tumor suppressor in cell proliferation, metastasis and epithelial-to-mesenchymal transition by targeting G-protein subunit alpha-13 in renal cell carcinoma. Gene 626, 275–281 (2017). https://doi.org/10.1016/j.gene.2017.05.040 CrossRefPubMedGoogle Scholar
- 38.L. Ng, T.M. Wan, J.H. Man, A.K. Chow, D. Iyer, G. Chen, T.C. Yau, O.S. Lo, D.C. Foo, J.T. Poon, W.K. Leung, R.W. Pang, W.L. Law, Identification of serum miR-139-3p as a non-invasive biomarker for colorectal cancer. Oncotarget 8, 27393–27400 (2017). https://doi.org/10.18632/oncotarget.16171 PubMedPubMedCentralGoogle Scholar